Lung cancer: personalised medicine

Poster Discussion
Chairs: J. Chorostowska-Wynimko (Warsaw, Poland), T. Blum (Berlin, Germany)

Hypofractionated radiotherapy for stage I lung carcinomas: moderate hypofractionation optimizes outcome I. Menoux (Strasbourg, France), D. Antoni (Strasbourg, France), P. Truntzer (Strasbourg, France), A. Keller (Strasbourg, France), G. Massard (Strasbourg, France), G. NoëL (Strasbourg, France)
Tyrosine-kinase inhibitors (TKI) in first-line treatment of patients with non-small cell lung cancer (NSCLC) - real life data from the Czech Republic. J. Skricková (Brno, Czech Republic), R. Chloupková (Brno, Czech Republic), Z. BortlícEk (Brno, Czech Republic), P. Brabec (Brno, Czech Republic), K. Hejduk (Brno, Czech Republic), L. DušEk (Brno, Czech Republic), M. PešEk (Plzen, Czech Republic), V. Kolek (Olomouc, Czech Republic), L. Koubková (Praha, Czech Republic), M. cErnovská (Praha, Czech Republic), F. Salajka (Hradec Králové, Czech Republic), M. Zemanová (Praha, Czech Republic), J. Krejcí (Praha, Czech Republic), H. cOupková (Brno, Czech Republic), M. šAtáNková (Brno, Czech Republic), A. Benejová (Brno, Czech Republic), M. TomíšKová (Brno, Czech Republic), J. Roubec (Ostrava, Czech Republic), I. GrygáRková (Olomouc, Czech Republic), L. Havel (Praha, Czech Republic), M. HrncIarik (Hradec Králové, Czech Republic), P. OpáLka (Praha, Czech Republic)
Adapalene abrogates erlotinib-induced skin disorder by regulating proinflammatory cytokine production from human epidermal cells N. Miwa (Kobe, Japan), T. Nagano (Kobe, Japan), D. Tamura (Kobe, Japan), R. Dokuni (Kobe, Japan), K. Umezawa (Kobe, Japan), N. Katsurada (Kobe, Japan), K. Nakata (Kobe, Japan), M. Yamamoto (Kobe, Japan), M. Tachihara (Kobe, Japan), H. Kamiryo (Kobe, Japan), K. Kobayashi (Kobe, Japan), Y. Nishimura (Kobe, Japan)
Clinical, histological and molecular characteristics of lung cancer in patients under 30 years-old. A. Ducroq (Rouen, France), M. Salaün (Rouen, France), N. Piton (Rouen, France), A. Lamy (Rouen, France), F. Guisier (ROUEN, France), L. Thiberville (Rouen, France)
Changes in targeted therapy and costs in NSCLC between 2009 and 2013 J. Walter (Neuherberg, Germany), R. Holle (Neuherberg, Germany), A. Tufman (München, Germany), L. Schwarzkopf (Neuherberg, Germany)
Accuracy of PD-L1 tumour staining of cytological and histological samples of lung adenocarcinoma C. Wagner (Melbourne, Australia), M. Christie (Melbourne, Australia), L. Irving (Melbourne, Australia), D. Steinfort (Melbourne, Australia)
Soluble sPD-L1 plasma concentrations in a series of 95 lung cancer patients D. Jovanovic (Belgrade, Republic of Serbia), J. Kotur Stevuljevic (Belgrade, Republic of Serbia), M. Roksandic-Milenkovic (Belgrade, Republic of Serbia), M. Simon (Cluj Našpoca, Romania), V. Ceriman (Belgrade, Republic of Serbia), S. Popevic (Belgrade, Republic of Serbia), I. Vukanic (Belgrade, Republic of Serbia), N. Samardžic (Belgrade, Republic of Serbia), M. Kontic (Belgrade, Republic of Serbia), B. Ilic (Belgrade, Republic of Serbia)
Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study C. Samaranayake (Brisbane, Australia), J. Coucher (Brisbane, Australia), E. Mccaffrey (Brisbane, Australia), M. Lehman (Brisbane, Australia), M. Murphy (Brisbane, Australia)
Inhaled immunotherapy for lung cancer? Certainly possible. P. Zarogoulidis (Thessaloniki, Greece), D. Tsiouda (Thessaloniki, Greece), A. Kallianos (AthensaathenaThessaloniki, Greece), A. Rapti (AthensAthensaathenaThessaloniki, Greece), C. Sardeli (AThessalonikithensAthensaathenaThessaloniki, Greece), H. Huang (ShanghaiAThessalonikithensAthensaathenaThessaloniki, China), W. Hohenforst-Schmidt (HofShanghaiAThessalonikithensAthensaathenaThessaloniki, Germany), G. Trakada (AthensHofShanghaiAThessalonikithensAthensaathenaThessaloniki, Greece), K. Sapalidis (ThessalonikiAthensHofShanghaiAThessalonikithensAthensaathenaThessaloniki, Greece)
Multimodal therapeutic approach for locally advanced NSCLC in everyday practice M. Roglic (Zagreb, Croatia), F. Popovic (Zagreb, Croatia), M. Labor (Osijek, Croatia), S. Badovinac (Zagreb, Croatia), M. KoršIc (Zagreb, Croatia), M. Jakopovic (Zagreb, Croatia), Z. Janevski (Zagreb, Croatia), J. Grah (Zagreb, Croatia)
The efficacy of induction chemoradiotherapy followed by surgery in stage IIIA-proven N2 NSCLC and the influence of lymph node downstage on the incidence of postoperative recurrence A. Tateishi (Kamogawaam, Japan), M. Misawa (Kamogawa, Japan), H. Nomori (Kamogawa, Japan), M. Nemoto (Kamogawa, Japan), R. Tsuzuki (Kamogawa, Japan), A. Otsuki (Kamogawa, Japan), K. Nakashima (Kamogawa, Japan), Y. Oyama (Kamogawa, Japan), H. Sugimura (Kamogawa, Japan), K. Shoji (Kamogawa, Japan), M. Aoshima (Kamogawa, Japan)
The efficacy and safety of induction chemoradiotherapy (ICRT) followed by surgery in stage III NSCLC patients (pts) with T3/4-adjacent organ invasion involved(AOI): A single-center retrospective observational study. M. Nemoto (Kamogawa, Japan), M. Misawa (Kamogawa, Japan), H. Nomori (Kamogawa, Japan), A. Tateishi (Kamogawa, Japan), R. Tsuzuki (Kamogawa, Japan), A. Otsuki (Kamogawa, Japan), K. Nakashima (Kamogawa, Japan), Y. Oyama (Kamogawa, Japan), H. Sugimura (Kamogawa, Japan), K. Shoji (Kamogawa, Japan), M. Aoshima (Kamogawa, Japan)
Survival impact of surgery in the treatment of stage IIIB-IVA non-small cell lung cancer S. Jang (Anyang, Republic of Korea), S. Park (Dongtan, Republic of Korea), C. Lee (Chuncheon, Republic of Korea), J. Park (Anyang, Republic of Korea), J. Kim (Anyang, Republic of Korea), S. Park (Anyang, Republic of Korea), Y. Hwang (Anyang, Republic of Korea), K. Jung (Anyang, Republic of Korea)
Changes of diffusing capacity after neoadjuvant concurrent chemoradiotherapy: implication on postoperative pulmonary complications in non-small cell lung cancer patients s. shin (seoul, Republic of Korea), Y. Choi (seoul, Republic of Korea), J. Jung (seoul, Republic of Korea), Y. Im (seoul, Republic of Korea), H. Park (seoul, Republic of Korea), J. Cho (seoul, Republic of Korea), H. Kim (seoul, Republic of Korea), J. Kim (seoul, Republic of Korea), J. Zo (seoul, Republic of Korea), Y. Shim (seoul, Republic of Korea), H. Lee (seoul, Republic of Korea), H. Park (seoul, Republic of Korea)
MONITORING IMMUNODYNAMICS IN IMMUNE CHECKPOINT INHIBITOR THERAPY FOR STAGE IIIB/IV NON-SMALL CELL LUNG CANCER D. Bento (Coimbra, Portugal), J. Almeida (Coimbra, Portugal), P. Couceiro (Coimbra, Portugal), V. Alves (Coimbra, Portugal), M. Santos-Rosa (Coimbra, Portugal), F. Barata (Coimbra, Portugal), P. Rodrigues-Santos (Coimbra, Portugal), A. Ferreira Rodrigues Figueiredo (Coimbra, Portugal)
A modified ILD-GAP index for patients with non-small cell lung cancer and interstitial lung disease H. Kobayashi (Shizuoka, Japan), T. Naito (Shizuoka, Japan), S. Omori (Shizuoka, Japan), K. Nakashima (Shizuoka, Japan), K. Wakuda (Shizuoka, Japan), A. Ono (Shizuoka, Japan), H. Kenmotsu (Shizuoka, Japan), H. Murakami (Shizuoka, Japan), M. Endo (Shizuoka, Japan), T. Takahashi (Shizuoka, Japan)
Management of concomitant COPD in patients with lung cancer M. Gottlieb (Hvidovre, Denmark), K. Marsaa (Herlev, Denmark), A. Mellemgaard (Herlev, Denmark), N. Godtfredsen (Hvidovre, Denmark)
Sleep disordered breathing and nocturnal hypoxemia are associated with an increased risk of lung cancer. M. Perez Warnisher (Madrid, Spain), L. Giraldo-Cadavid (Bogotá, Colombia), H. Oliveros (Cundinamarca, Colombia), E. Cabezas (Madrid, Spain), F. Troncoso (Madrid, Spain), T. Gómez (Madrid, Spain), R. Melchor (Madrid, Spain), E. Pinillos (Madrid, Spain), A. El Hachem (Madrid, Spain), C. Gotera (Madrid, Spain), P. Rodriguez (Madrid, Spain), N. González-Mangado (Madrid, Spain), G. Peces-Barba (Madrid, Spain), L. Seijo (Madrid, Spain)